Navigation Links
Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
Date:11/23/2008

erol. In addition, placebo adjusted weight loss exceeding 5% in an 8-week placebo controlled study and 10% in a 6-month study has been demonstrated. Composition of matter, formulation and method of use patents for DCCR have been filed worldwide. A fixed dose combination product with a statin is under development.

About Very High Triglycerides

Hypertriglyceridemia, a disease where patients have high blood levels of triglycerides, is associated with increased risk of coronary heart disease even after LDL-cholesterol targets have been achieved. Very high triglycerides are associated with an increased risk of developing pancreatitis. There are approximately 5 million patients in the US with very high triglycerides. The leading products for treating very high triglycerides, fenofibrate and omega-3 fatty acids, while effective, also cause significant elevations in LDL-cholesterol.

About Mixed Dyslipidemia

The prevalence of mixed dyslipidemia (characterized by elevated triglycerides and low HDL-cholesterol), is currently more than 16 million patients in the US and is rising in tandem with the ongoing obesity epidemic. Treatment options are limited and the leading products are associated with tolerability issues including flushing, elevated liver enzymes and increased risk of rhabdomyolysis when used in combination with statin drugs.

About Essentialis

Essentialis is a pharmaceutical company based in Carlsbad, CA focused on the development of breakthrough medicines for the treatment of cardiovascular and metabolic diseases. The company's portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases. The company's lead product is in Phase 2 studies in dyslipidemic subjects and is entering a Phase 1 study in type I diabet
'/>"/>

SOURCE Essentialis Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
2. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
3. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
4. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
7. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
10. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
11. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. Titled ... model developed at UH to enhance care for adult ... need for high health care utilization.  ...
(Date:7/10/2014)... DIEGO , July 10, 2014  RESMED INC. (NYSE: ... its fourth quarter and fiscal year ended June 30, 2014 ... Stock Exchange market close. A press release with ResMed,s results ... the company will host a webcast to discuss operating results ... to begin at 1:30 p.m. US Pacific Time and the ...
(Date:7/10/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... sale to Galderma of all rights to Restylane, Perlane, ... for $1.4 billion in cash, pursuant to the previously ... acquisition of Galderma. "We are pleased ... company that is firmly committed to the aesthetic dermatology ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... 30, 2011 David N. Jonas, CEO, PharMEDium ... investments for innovations with an unprecedented focus on ... with a steady stream of technologically-driven service advancements.  Working ... safety and quality , PharMEDium ...
... 30, 2011 Reportlinker.com announces that a new ... catalogue: Pharmaceutical Distributors - ... This register contains information ... Europe. The register includes the following information ...
Cached Medicine Technology:PharMEDium's Technology Helps Hospital Pharmacists Ensure Safety 2
(Date:7/11/2014)... July 11, 2014 Global enterprises today ... to outsource day-to-day management activities. Managed services offer these ... expenses. The economic slowdown resulted into rising operational costs ... expenses is considered to be the global market driver ... , The global managed services market is estimated to ...
(Date:7/11/2014)... Presently, disposable medical suppliers call for ... supplies segment. During the past two decades, the world ... an average 12.5% per year), primarily owing to the ... US is the largest market for disposable medical supplies ... The second position is held by Europe with a ...
(Date:7/11/2014)... The Miriam Hospital have found that people with ... rates of smoking than those without mobility impairments. ... to attempt quitting than those without mobility impairments, ... for this population. The study and its findings ... the American Journal of Public Health . ...
(Date:7/11/2014)... has found that organic foods and crops have ... including more antioxidants and fewer, less frequent pesticide ... 343 peer-reviewed publications comparing the nutritional quality and ... fruits, vegetables, and grains. The study team applied ... and non-organic foods. , "Science marches on," ...
(Date:7/11/2014)... (HealthDay News) -- Delaying surgery to repair damage to the ... middle of the knee -- could increase a young athlete,s ... medical records of 130 patients, aged 8 to 16, who ... less than six weeks after their injury, 37 had surgery ... more than three months after their injury. The youngsters ...
Breaking Medicine News(10 mins):Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Miriam Hospital study examines smoking prevalence 2Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2
... Severe early childhood caries can destroy most of a ... populations, including American Indians and Alaskan natives. Although the ... early childhood caries has been known for almost a ... are responsible for the disease has remained elusive. ...
... The American College of Physicians (ACP) today told the ... including enacting a permanent end to scheduled Medicare sustainable ... for Congress to act was demonstrated by today,s release ... across-the-board cut in Medicare payments to doctors on January ...
... (HealthDay News) -- Allergy shots are time-tested treatments ... relief to allergy sufferers within weeks instead of months, ... currently given under the skin (subcutaneously), new methods of ... week,s annual scientific meeting of the American College of ...
... N.C. -- For the first time, researchers have ... successfully reverse the severe, crippling bleeding disorder hemophilia ... the development of new therapies for human patients. ... Institute for Regenerative Medicine, collaborating with other institutions, ...
... Reporter , WEDNESDAY, Nov. 2 (HealthDay News) -- A compound ... hard-to-treat hemophilia patients also seems to be effective in preventing ... published in the Nov. 3 edition of the New ... didn,t last long, the results do raise the possibility that, ...
... locally advanced or high-risk prostate cancer who receive combined ... likely to die from their disease, shows clinical research ... (PMH) Cancer Program, University Health Network. The ... (doi: 10.1016/S0140-6736(11)61095-7). Principal investigator Padraig Warde, deputy head, ...
Cached Medicine News:Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 2Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 3Health News:Congress must 'go big' on physician payment reform 2Health News:Congress must 'go big' on physician payment reform 3Health News:Improved Allergy Shots Might Be on Horizon 2Health News:Gene therapy shows promise as hemophilia treatment in animal studies 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 3Health News:Radiation plus hormone therapy greatly improves survival 2
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ... angle required for large and small joint ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
Medicine Products: